202 Chapter 6 19. Barba-Romero, M.Á., et al., Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy. Medicina Clínica, 2019. 153(2): p. 47-55. 20. Germain, D.P., et al., The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Molecular genetics and metabolism reports, 2019. 19: p. 100454-100454. 21. Elstein, D., et al., X-inactivation in Fabry disease. Gene, 2012. 505(2): p. 266-8. 22. van der Veen, S.J., et al., Developments in the treatment of Fabry disease. J Inherit Metab Dis, 2020. 43(5): p. 908-921. 23. Körver, S., et al., Determinants of cerebral radiological progression in Fabry disease. Journal of Neurology, Neurosurgery & Psychiatry, 2020. 91(7): p. 756. 24. El Sayed, M., et al., ECG Changes during Adult Life in Fabry Disease: Results from a Large Longitudinal Cohort Study. Diagnostics, 2023. 13(3): p. 354. 25. Maceira, A.M., et al., Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 2006. 8(3): p. 417-26. 26. Mason, J.W., et al., Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol, 2007. 40(3): p. 228-34. 27. Namdar, M., et al., PQ interval in patients with Fabry disease. Am J Cardiol, 2010. 105(5): p. 753-6. 28. Platonov, P.G., P-wave morphology: underlying mechanisms and clinical implications. Ann Noninvasive Electrocardiol, 2012. 17(3): p. 161-9. 29. Wu, J.C., et al., Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J, 2010. 31(9): p. 1088-97. 30. Olivotto, I., et al., Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol, 2005. 46(3): p. 480-7. 31. Lang, R.M., et al., Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 2015. 16(3): p. 233-70. 32. Sharp, A.S., et al., Tissue Doppler E/E’ ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J, 2010. 31(6): p. 747-52. 33. Saito, C., et al., Prognostic Relevance of a Score for Identifying Diastolic Dysfunction according to the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations in Patients with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr, 2022. 35(5): p. 469-476. 34. Özbek, B.T., et al., Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study. Diabetic Medicine, 2021. 38(10): p. e14627. 35. Behera, M.K., et al., Diastolic Dysfunction Is a Predictor of Poor Survival in Patients with Decompensated Cirrhosis. Int J Hepatol, 2021. 2021: p. 5592376. 36. Lu, D.-Y., et al., Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy. American Heart Journal, 2020. 219: p. 58-69.
RkJQdWJsaXNoZXIy MTk4NDMw